Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology

Building Your Foundation: Understanding Encapsulating Peritoneal Sclerosis

At a Glance

Encapsulating peritoneal sclerosis is a rare, serious scarring condition linked most strongly to longer time on peritoneal dialysis. It can become apparent after dialysis stops or a transplant, but no single safe time limit or cause predicts who will develop it.

Receiving a diagnosis of Encapsulating Peritoneal Sclerosis (EPS) can be a deep shock, especially if it arrives just as you were transitioning away from dialysis or celebrating a successful kidney transplant. EPS is a rare but serious condition where the peritoneum (the thin membrane lining your abdomen) becomes a thick, fibrous, and scarred shell [1]. This “cocoon” eventually encases and squeezes the intestines, preventing them from moving freely and potentially leading to bowel obstructions [2].

Because EPS is so uncommon, it is likely that your local medical team has limited direct experience with it [3]. Understanding the mechanisms behind this disease and its relationship to your time on dialysis can help you navigate the complex path toward management and recovery.

The Role of Time and Exposure

The single most significant factor in developing EPS is the total amount of time spent on Peritoneal Dialysis (PD) [4]. While many people use PD for years without complication, the risk increases the longer the membrane is exposed to dialysis fluid [5].

Research shows a clear trend of rising risk over time, though specific percentages vary significantly between different patient groups and studies. These figures are not a single timeline of your personal risk, but rather snapshots from different medical cohorts:

  • A Scottish Cohort Study: Found that the cumulative incidence of developing EPS was about 1.1% by 1 year, 9.4% by 5 years, and 22.2% by 7 years on PD [5].
  • An Australia/New Zealand Cohort: Found a much lower overall prevalence of 0.4% [6].
  • A Taiwanese Study: Suggested that patients on PD for more than 10 years had significantly higher odds of diagnosis compared to those who stopped earlier (an Odds Ratio of 5.5) [7].

Because the disease is rare, these numbers may seem alarming, but they highlight why doctors monitor long-term PD patients so closely for signs of membrane change.

The “Two-Hit” Hypothesis

Researchers often use a proposed model called the two-hit hypothesis to explain how EPS might develop [1]. It suggests that the disease often involves two distinct stages of injury, though many patients never have a clearly identifiable second event.

The First Hit: Chronic Injury

The “first hit” is the years of daily exposure to standard PD fluids [8]. These fluids can gradually damage the delicate protective top layer of the peritoneum [1]. Over time, this causes chronic inflammation and a “simple” form of scarring that makes the membrane less efficient [9].

The Second Hit: The Proposed Trigger

The “second hit” is an acute event that may trigger or reveal the thickened membrane [10]. Common proposed triggers include:

  • Severe or Prolonged Peritonitis: A serious infection of the abdominal lining [11].
  • PD Withdrawal: Stopping PD or switching to hemodialysis is associated with the clinical appearance of EPS, though it is not definitively proven that stopping PD causes it [12].
  • Kidney Transplantation: In some patients, the surgery or the transition off dialysis may coincide with the membrane transitioning into EPS [13].

While the “first hit” (PD duration) is universally recognized, scientists are still working to understand exactly why some people experience a “second hit” while others do not [14]. Please remember that developing EPS is not your fault, and it is not a direct result of something you or your doctors did wrong during your transplant.

The Emotional Impact of the Diagnosis

Approximately 75% of cases are identified only after a patient has stopped peritoneal dialysis, often when they have moved to hemodialysis or received a kidney transplant [12].

It is completely normal to feel shocked, angry, or let down when you are diagnosed with a new, life-altering complication just as you thought you were gaining your freedom from dialysis [4]. The combination of recurrent bowel issues, pain, and the need for intense nutritional support can significantly impact your quality of life [15][2]. Validating these feelings is a vital part of your care; the psychological burden of EPS is heavy, and you deserve support for your mental health alongside your physical treatment [16][17].

What Science Knows (and Doesn’t Know)

Medical consensus is clear on certain aspects of EPS, while others remain areas of active research:

  • What is certain: The length of time you spend on PD is the primary driver of risk [4]. Improving the “biocompatibility” of dialysis fluids may help reduce the initial injury [8].
  • What is uncertain: There is no universal “safe” cutoff for how many years a person can stay on PD [18]. The exact biological mechanism that turns simple scarring into full encapsulation is still not fully understood, nor is the best way to prevent it after a transplant [14][19].

Because of these uncertainties, your care should be highly individualized and managed by a team that understands the complexities of your specific history [19].

Common questions in this guide

What is encapsulating peritoneal sclerosis?
EPS is a rare, serious condition in which the lining of the abdomen becomes thick and scarred. The scar tissue can form a shell around the intestines, restrict their movement, and cause bowel obstruction or difficulty maintaining nutrition.
Does spending more time on peritoneal dialysis raise my risk of EPS?
Yes. The longer the abdominal lining is exposed to peritoneal dialysis fluid, the more the risk increases, although there is no single number of years that is considered safe for everyone. Risk estimates differ among patient groups, so duration alone cannot predict an individual outcome.
Can EPS appear after I stop peritoneal dialysis or receive a kidney transplant?
EPS is often recognized after peritoneal dialysis has stopped, including after a switch to hemodialysis or a kidney transplant. Stopping dialysis or transplantation may coincide with the condition becoming apparent, but it has not been proven that either event directly causes EPS.
Can peritonitis trigger encapsulating peritoneal sclerosis?
Severe or prolonged peritonitis is one proposed second hit that may trigger or reveal EPS after long-term injury to the abdominal lining. However, not everyone with EPS has a clearly identifiable second event, and peritonitis is not the only factor involved.
Did I cause EPS by stopping dialysis or having a transplant?
No. EPS results from complex changes in the abdominal lining, and developing it is not your fault or proof that you or your doctors did something wrong. Your care team can review your history without assuming blame.
What kind of care team and support are useful for EPS?
Because EPS can affect the intestines, nutrition, kidney care, and emotional well-being, care may involve a multidisciplinary team with kidney specialists, surgeons, nutrition professionals, and mental-health support. Ask whether your hospital has experience managing this rare condition and how your eating, energy, bowel health, and mood will be monitored.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Encapsulating peritoneal sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my history of peritoneal dialysis and any recent peritonitis episodes, how would you describe my individual risk profile for EPS?
  2. 2.Since EPS is rare, does our hospital have a specialized multidisciplinary team—including surgeons and nutritionists—who are experienced in managing this condition?
  3. 3.What might have contributed to my condition, and does that influence how we should approach my current treatment?
  4. 4.How will my kidney transplant (or recent switch to hemodialysis) affect the progression or management of EPS?
  5. 5.What are our long-term goals for my nutrition and gastrointestinal health, and how will we monitor my progress?

References

References (19)
  1. 1

    Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease.

    Moinuddin Z, Summers A, Van Dellen D, et al.

    Frontiers in physiology 2014; (5()):470 doi:10.3389/fphys.2014.00470.

    PMID: 25601836
  2. 2

    Surgical Management of Encapsulating Peritoneal Sclerosis: A Case Report in Kidney Transplant Patient.

    Shahbazov R, Talanian M, Alejo JL, et al.

    Case reports in surgery 2018; (2018()):4965459 doi:10.1155/2018/4965459.

    PMID: 29682387
  3. 3

    Designing Epidemiology Studies to Determine the Incidence and Prevalence of Encapsulating Peritoneal Sclerosis (EPS).

    Nitsch D, Davenport A

    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 2015; (35(7)):678-82 doi:10.3747/pdi.2015.00186.

    PMID: 26703844
  4. 4

    Risk factors for Encapsulating Peritoneal Sclerosis in patients undergoing peritoneal dialysis: A meta-analysis.

    Li D, Li Y, Zeng H, Wu Y

    PloS one 2022; (17(3)):e0265584 doi:10.1371/journal.pone.0265584.

    PMID: 35312717
  5. 5

    Incidence and outcome of encapsulating peritoneal sclerosis.

    Petrie MC, Traynor JP, Mactier RA

    Clinical kidney journal 2016; (9(4)):624-9 doi:10.1093/ckj/sfw051.

    PMID: 27478609
  6. 6

    Encapsulating peritoneal sclerosis in an Italian center: thirty year experience.

    Vizzardi V, Sandrini M, Zecchini S, et al.

    Journal of nephrology 2016; (29(2)):259-267 doi:10.1007/s40620-015-0241-x.

    PMID: 26521254
  7. 7

    Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS.

    Tseng CC, Chen JB, Wang IK, et al.

    PloS one 2018; (13(1)):e0190079 doi:10.1371/journal.pone.0190079.

    PMID: 29293548
  8. 8

    Recent Understanding of Peritoneal Pathology in Peritoneal Dialysis Patients in Japan.

    Hamada C, Tomino Y

    Blood purification 2021; (50(6)):719-728 doi:10.1159/000510282.

    PMID: 33567422
  9. 9

    Current Progress in Peritoneal Dialysis: A Narrative Review of Progress in Peritoneal Dialysis Fluid.

    Hashimoto K, Kamijo Y

    Life (Basel, Switzerland) 2025; (15(2)) doi:10.3390/life15020279.

    PMID: 40003688
  10. 10

    Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.

    Jagirdar RM, Bozikas A, Zarogiannis SG, et al.

    International journal of molecular sciences 2019; (20(22)) doi:10.3390/ijms20225765.

    PMID: 31744097
  11. 11

    Risk factors for encapsulating peritoneal sclerosis: Analysis of a 36-year experience in a University Hospital.

    Nakao M, Yamamoto I, Maruyama Y, et al.

    Nephrology (Carlton, Vic.) 2017; (22(11)):907-912 doi:10.1111/nep.12911.

    PMID: 27556577
  12. 12

    [Encapsulating peritoneal sclerosis].

    Ryckelynck JP, Béchade C, Bouvier N, et al.

    Nephrologie & therapeutique 2017; (13(4)):211-219 doi:10.1016/j.nephro.2017.01.020.

    PMID: 28576435
  13. 13

    mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience.

    Messina M, Ariaudo C, Mella A, et al.

    Journal of nephrology 2015; (28(2)):245-9 doi:10.1007/s40620-014-0168-7.

    PMID: 25585825
  14. 14

    [A case of encapsulating of peritoneal sclerosis with fast and ominous evolution].

    Li Cavoli G, Tralongo A, Arena N, et al.

    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 2016; (33(2)).

    PMID: 27067218
  15. 15

    Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients.

    Tawada M, Ito Y, Hamada C, et al.

    PloS one 2016; (11(4)):e0154644 doi:10.1371/journal.pone.0154644.

    PMID: 27119341
  16. 16

    10-year-long survival in a PD patient with severe calcifying encapsulating peritoneal sclerosis treated with tamoxifen: a case-report.

    Liakopoulos V, Georgianos PI, Vaios V, et al.

    BMC nephrology 2020; (21(1)):110 doi:10.1186/s12882-020-01769-x.

    PMID: 32234031
  17. 17

    Improvement of Encapsulating Peritoneal Sclerosis After Medical Treatment and Successful Deceased Donor Kidney Transplant in a Child: A Case Report.

    Al Riyami MS, Altalebi A, Al Hashmi S, et al.

    Pediatric transplantation 2024; (28(7)):e14867 doi:10.1111/petr.14867.

    PMID: 39320007
  18. 18

    New Japanese Society of Dialysis Therapy Guidelines for Peritoneal Dialysis.

    Ito Y, Tawada M, Yuasa H, Ryuzaki M

    Contributions to nephrology 2019; (198()):52-61 doi:10.1159/000496523.

    PMID: 30991403
  19. 19

    Encapsulating peritoneal sclerosis.

    Garosi G, Mancianti N, Corciulo R, et al.

    Journal of nephrology 2013; (26 Suppl 21()):177-87 doi:10.5301/JN.2013.11640.

    PMID: 24307446

This page explains EPS risk factors and the proposed two-hit mechanism for informational purposes only and does not constitute medical advice. Ask your nephrology and transplant team to interpret your history and plan care for your specific situation.